Carbon-ion minibeam radiotherapy faces major dosimetry and motion barriers before clinical use

Carbon-ion minibeams show preclinical tissue-sparing potential, but high-LET dosimetry, biological dose heterogeneity and organ motion remain major barriers to clinical translation.

KEY POINTS

  • This narrative review from Heidelberg University Hospital and the German Cancer Research Center (DKFZ) examines carbon-ion minibeam radiotherapy (CIMRT), an experimental technique combining the higher linear energy transfer (LET) and relative biological effectiveness (RBE) of carbon ions with spatially fractionated irradiation. Minibeam fields contain narrow high-dose peaks separated by low-dose valleys, typically using peak widths of approximately 0.2–1.0 mm and valley regions of 1–4 mm, with the aim of preserving normal tissues while maintaining tumor irradiation.
  • Compared with proton minibeams, carbon ions undergo less lateral scattering, potentially preserving sharper peak-to-valley dose patterns at greater depths. However, reduced scattering also makes it more difficult to achieve homogeneous tumor coverage, while nuclear fragmentation produces secondary particles beyond the primary ion range. The review describes emerging approaches such as carbon-ion scissor beams, which use slightly offset beam directions to preserve spatial modulation in normal tissue while producing a more homogeneous target dose; these strategies remain computational and experimental.
  • Carbon-ion minibeam experiments have demonstrated technical feasibility and early biological activity, but the evidence remains sparse. In an early rabbit brain model, a single exposure of 40 Gy physical dose produced no observable cognitive impairment, with MRI and histopathology showing substantial normal-tissue preservation at six months. In a separate murine osteosarcoma model, tumor growth delay was observed even though only approximately 30% of the tumor volume received peak doses exceeding 100 Gy, while the remaining tissue received valley doses of approximately 1.5 Gy. These results cannot establish equivalent safety or tumor control in humans.
  • Experimental beam characterization demonstrates how rapidly minibeam geometry changes with depth. One tungsten multislit collimator used 2.1-mm leaves and 0.7-mm slits, producing minibeams with 0.7-mm full width at half maximum and 3.2-mm center-to-center spacing. The measured peak-to-valley dose ratio (PVDR) decreased from approximately 60 to 10 over 80 mm of penetration, highlighting the importance of depth, scattering and beam configuration. Moreover, higher RBE in low-dose valleys may reduce the biologically weighted PVDR relative to the physical PVDR.
  • Reliable dosimetry remains a central challenge because of submillimeter dose gradients and high-LET radiation fields. Radiochromic films provide high-resolution two-dimensional measurements but are affected by LET-dependent quenching, whereas microDiamond detectors offer real-time point measurements but may overrespond by less than approximately 5% at LET values up to 200 keV/µm, increasing toward 10% around 250 keV/µm. CMOS detectors provide spatially resolved measurements but introduce temperature sensitivity and radiation-damage concerns; emerging fluorescent nuclear track detectors and optically stimulated luminescence films require further validation.
  • Organ motion can substantially degrade the intended spatial dose distribution, particularly for abdominal and thoracic targets. In a pancreatic motion-phantom experiment, 15-mm cranio-caudal respiratory displacement reduced normal-tissue PVDR by approximately 60% and target dose by approximately 25%. Respiratory gating, tumor tracking, rescanning and rapid delivery are potential mitigation approaches, but their effectiveness for maintaining carbon-ion minibeam patterns remains insufficiently established. Dynamic anthropomorphic phantoms, including the Pancreas Phantom for Ion beam Therapy (PPIeT), offer platforms for validating these approaches under more realistic conditions.
  • Clinical translation requires progress beyond beam generation and static phantom measurements. The review highlights the need for standardized high-resolution dosimetry, LET- and RBE-aware treatment planning, motion-robust delivery, clinically realistic phantom validation and additional in vitro and in vivo experiments. Although the first patients have received orthovoltage minibeam radiotherapy, these treatments did not use carbon ions; CIMRT itself remains preclinical, with no established clinical dose constraints, validated normal-tissue benefit or patient-outcome evidence.

CLINICAL TAKEAWAY

Carbon-ion minibeam radiotherapy is a promising experimental approach that seeks to combine high-LET tumor irradiation with spatial normal-tissue sparing, potentially benefiting tumors located near radiosensitive structures. However, uncertainty in biological dose distribution, detector response and motion-induced degradation remains substantial, and the limited preclinical evidence does not yet support routine clinical treatment or a demonstrated therapeutic advantage over conventional carbon-ion radiotherapy.

SOURCE

Zeitschrift für Medizinische Physik

Browse more research Suggest a correction